acute kidney injury
Conditions
Interventions
NO group:NO group will receive 40 ppm inhaled NO during CPB through the membrane oxygenator, followed by continuously administration of 40 ppm NO through the ventilator circuit until 12 hours after su
Control Group:NO therapy is not used during CPB or after surgery
routine surgical management and treatment measures are followed.
Sponsors
Fuwai Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age =18 years old 2. Planning to undergo heart surgery with cardiopulmonary bypass, with an expected bypass time of over 90 minutes; the planned heart surgeries include: Simple coronary artery bypass grafting (CABG) Simple valve surgery Combined surgeries [combined valve surgery (mitral valve repair/replacement and aortic valve repair/replacement); CABG plus valve surgery (mitral valve repair/replacement and/or aortic valve repair/replacement); valve surgery (mitral valve repair/replacement and/or aortic valve repair/replacement); aortic surgery (major vessels surgery without deep hypothermic circulatory arrest); CABG plus aortic surgery (major vessels surgery without deep hypothermic circulatory arrest)] 3. Meet the CHF diagnostic criteria 4. Study participants sign written informed consent and acknowledge the risks and benefits stated in the consent form.
Exclusion criteria
Exclusion criteria: 1. Participated in another clinical trial within the past 1 month; 2. Age <18 years; 3. Undergoing emergency surgery; 4. Undergoing LVAD surgery, heart transplant, or combined heart-lung transplant; 5. Undergoing a second chest surgery; 6. Undergoing hybrid surgery; 7. Undergoing major vascular surgery requiring deep hypothermic circulatory arrest under cardiopulmonary bypass; 8. Preoperative hemodynamic instability (systolic BP <90 mmHg) or preoperative use of vasoactive drugs; 9. Preoperative (from admission to surgery) acute kidney injury defined by KDIGO criteria (serum creatinine rise =26.5 µmol/L within 48 hours, or a rise to =1.5 times baseline within 7 days); 10. Preoperative CKD stage 4-5 or using renal replacement therapy; 11. Having severe infection, tumors, active bleeding, or severe liver, lung, or kidney disease; 12. Allergic to NO or contraindicated: known history of allergy to inhaled NO or severe adverse reactions; 13. Known hemolysis (intravascular or extravascular) before surgery; 14. Preoperative hemoglobin <90 g/L; 15. Or other conditions that the investigator considers unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of AKI within 7 days after cardiac surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| AKI stage within 7 days after cardiac surgery;The levels of plasma neutrophil gelatinase-associated lipocalin (NGAL);The levels of plasma malondialdehyde (MDA);Major perioperative complications;duration of postoperative mechanical ventilation;Length of ICU stay;Length of hospital stay;in-hospital mortality; | — |
Countries
China
Contacts
Public ContactBingyang Ji
Fuwai Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed